Stock RSPI RESPIRERX PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages RespireRx Pharmaceuticals Inc.

Equities

RSPI

US7612273059

Market Closed - OTC Markets
Other stock markets
 01:25:31 04/05/2024 am IST 		5-day change 1st Jan Change
0.0009 USD -18.18% Intraday chart for RespireRx Pharmaceuticals Inc. 0.00% 0.00%
10/04 RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding CI
20/03 RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors
Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
RespireRx Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt
RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders
RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects Without Sedation
Respirerx Pharmaceuticals Inc. Announces Appointment of Joseph Siegelbaum as Independent Member of the Board of Directors
ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd
RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
RespireRx Pharmaceuticals Inc. Announces Board Changes
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of Gabakine Neuromodulators for the Treatment of Tinnitus
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RSPI Stock
  4. News RespireRx Pharmaceuticals Inc.
  5. Other languages